Kaizen Advisory’s Supernus Pharmaceuticals SUPN Stock Holding History

Kaizen Advisory’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$630K	Sell	18,946 -3,775	-17%	-$162K	0.44%	80
2018 Q3	$1.14M	Sell	22,721 -6,136	-21%	-$303K	0.6%	22
2018 Q2	$1.73M	Buy	28,857 +21,692	+303%	+$1.12M	0.88%	6
2018 Q1	$328K	Buy	+7,165	New	+$299K	0.32%	17

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Kaizen Advisory's SUPN Position: Q4 2018 in Review

Kaizen Advisory reduced its Supernus Pharmaceuticals (SUPN) stake by 17% in Q4 2018, selling an estimated $162K and leaving 18,946 shares worth $630K. The position accounts for 0.44% of the portfolio, ranked #80.

Kaizen Advisory first reported a position in SUPN in Q1 2018 and has held it in 4 quarters since. The position peaked at $1.73M in Q2 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

Kaizen Advisory held 18,946 shares of Supernus Pharmaceuticals worth $630K as of Q4 2018.
Kaizen Advisory sold 3,775 Supernus Pharmaceuticals shares in Q4 2018, an estimated $162K.
Supernus Pharmaceuticals made up 0.44% of Kaizen Advisory's portfolio in Q4 2018, its #80 holding.
Kaizen Advisory first reported a position in Supernus Pharmaceuticals in Q1 2018 and has held it in 4 quarters since.
Kaizen Advisory's Supernus Pharmaceuticals position peaked at $1.73M in Q2 2018.
274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on Kaizen Advisory's 13F filing for Q4 2018, filed 15 Feb 2019.